Weill Cornell Medicine researchers received a $1 million PCF Challenge Award to develop an AI model for early detection of treatment-resistant prostate cancer subtypes.
Key Details
- 1Dr. Ekta Khurana leads the project, collaborating with Memorial Sloan Kettering Cancer Center.
- 2The team received a $1 million, two-year Prostate Cancer Foundation Challenge Award.
- 3Research focuses on AI models trained on pathology slides, gene activity, and treatment outcomes.
- 4Project aims to identify patients with tumors likely to develop resistance early so they can be matched to appropriate trials.
- 5Validation of the developed AI model in clinical trials is planned for a follow-on project.
Why It Matters
Developing AI tools to distinguish treatment-resistant tumor subtypes could significantly improve personalized care and trial selection for prostate cancer, addressing a pressing clinical need. Integration of pathology, genomics, and AI in this way is at the forefront of imaging-based precision medicine.
Source
EurekAlert
Related News
•EurekAlert
New Framework Compares AI Segmentation Without Ground Truth Annotations
Researchers introduce an open-source approach for evaluating AI anatomy segmentation models in medical imaging without requiring ground truth annotations.
•EurekAlert
HKU Develops AI-Enabled Optical Device for Rapid, Non-Invasive Cancer Risk Assessment
The University of Hong Kong has introduced a portable AI-enabled optical device for rapid, non-invasive cancer risk detection using saliva samples.
•EurekAlert
AI-Driven Handheld Endomicroscope Enhances Early Cancer Detection
Researchers develop PrecisionView, a handheld AI-powered endomicroscope for real-time, high-resolution cancer diagnostics.